Phase III study of ibrutinib combined with bendamustine and rituximab in previously treated patients with CLL/SLL

In the Phase III HELIOS trial, patients were randomized to therapy with either bendamustine and rituximab or bendamustine and rituximab in combination with ibrutinib. In this video, expert Jacqueline Barrientos (North Shore-LIJ, NYA, USA) further explains the impressive data and its possible impact on clinical practice.

The HELIOS trial protocol was outlined in an article published in Future Oncology earlier this year. Click here to read this open access article.